SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 1, 2026

PCSA

Processa Pharmaceuticals, Inc.
BULLISH
Impact 5/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $11K total
Actionable Insight ▲ Bullish

Two senior insiders (CFO and President of R&D) made open-market purchases at $1.93, the first insider buying in this window. Monitor for any 8-K or press release that could explain the buying; absent that, treat as a low-conviction signal.

DirectionBullish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
PCSA ▼ -14.81% at T+60d
LONG call ✗ call lost -14.81% · α vs SPY -17.87% · entry $2.16 → $1.84
Entry = T+0 close
Jul 1, 2026
via day close
T+1d
-2.78%
call -2.78% · α -3.65%
$2.10
settled 4mo ago
T+5d
0.00%
call 0.00% · α -1.37%
$2.16
settled 4mo ago
T+20d
-0.46%
call -0.46% · α -0.77%
$2.15
settled 3mo ago
T+60d
-14.81%
call -14.81% · α -17.87%
$1.84
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Two C-suite insiders (CFO and President of R&D) made open-market purchases totaling ~$11K on June 30, 2026, at $1.93/share. This is the first insider buying in this cluster window and represents ~0.22% of the company's $5M market cap — a modest but notable signal from senior management.

Key Financial Metrics

Direction
buying
Total Value
$11.2K
Insiders
2

Key Facts

  • CFO Russell Skibsted purchased 3,277 shares at $1.93 for $6,325 on June 30, 2026
  • President of R&D David Young purchased 2,531 shares at $1.93 for $4,885 on June 30, 2026
  • Total open-market purchases: $11,209, representing ~0.22% of the $5M market cap
  • Five directors exercised derivative securities for 203 shares each at $0 (non-cash, no economic signal)
  • Prior 30-day insider activity: 2 buys totaling $11K — this cluster is the same activity

Financial Impact

Two C-suite insiders purchased $11,209 in open-market shares, representing ~0.22% of the $5M market cap

insider ownershipcash deployment

Risk Factors

  • Total insider buying of $11K is only 0.22% of market cap — a modest signal that may not move the stock
  • Micro-cap biotech ($5M market cap) with no disclosed revenue or pipeline catalysts — binary risk profile
  • Derivative exercises by directors are non-cash events with no economic signal

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCSA-1782976493664
14 reports for PCSA
Performance horizon
70% Hit rate @ T+5 7 of 10 directional calls Went positive at some point 9 of 11 best @ T+5▲ +19.60%Mar 31, 2026
Filters
Rows
Reports for PCSA — sortable, filterable
TypeNow
Oct 26, 2026
1d ago
EFFECT
BEARISH ★ 6/10
$1.80awaiting T+5—$1.82 (−1.39%)
Oct 22, 2026
5d ago
DEF 14A
NEUTRAL ★ 4/10
$1.81awaiting T+5—$1.82 (+0.55%)
Oct 9, 2026
18d ago
S-3
BEARISH ★ 7/10
$1.90 $1.73▲ +8.95%▲ +7.45%$1.82 (+4.21%)
Jul 29, 2026
12w ago
8-K
MIXED ★ 6/10
$2.03 $2.19▲ +7.88%▲ +2.35%$1.82 (−10.34%)
Jul 1, 2026
16w ago
Insider Cluster
BULLISH ★ 5/10
$2.16 $2.16· 0.00%▼ −1.37%$1.82 (−15.74%)
Jun 16, 2026
19w ago
Insider Cluster
BULLISH ★ 5/10
$2.15 $1.93▼ −10.23%▼ −9.19%$1.82 (−15.35%)
Jun 16, 2026
19w ago
Insider Cluster
BULLISH ★ 4/10
$2.15 $1.93▼ −10.23%▼ −9.19%$1.82 (−15.35%)
Jun 1, 2026
21w ago
Insider Cluster
BULLISH ★ 4/10
$2.92 $2.04▼ −30.31%▼ −27.34%$1.82 (−37.67%)
May 19, 2026
23w ago
Insider Cluster
BULLISH ★ 5/10
$2.61 $2.64▲ +1.15%▼ −0.65%$1.82 (−30.27%)
May 19, 2026
23w ago
Insider Cluster
BULLISH ★ 5/10
$2.61 $2.64▲ +1.15%▼ −0.65%$1.82 (−30.27%)
Showing 10 of 14

US Market Status

Market Closed — Opens Thu (11h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026